Robert E. Kalb, MD
Adjunct Professor of Dermatology
Department: Dermatology
Contact information
Buffalo Medical Group
325 Essjay Road
Suite 210
Buffalo, NY 14221
325 Essjay Road
Suite 210
Buffalo, NY 14221
Office: 716-630-1102
Fax: 716-633-6507
Fax: 716-633-6507
Education:
B.S. (Biochemistry, summa cum laude)
State University of New York at Buffalo, 1978.
M.D. (cum laude)
Downstate Medical Center, 1982.
Permanent linkB.S. (Biochemistry, summa cum laude)
State University of New York at Buffalo, 1978.
M.D. (cum laude)
Downstate Medical Center, 1982.
Selected Publications
Mogavero, A; Kalb, RE.: Darier's disease in Decision Support in Medicine. https://www.decisionsupportinmedicine.com. Anderson, B; Heymann, W;Hivnor, CM; Lessin, SR. (eds.). 2017.Kalb, RE.: Pustular psoriasis: Management. UpToDate, Post TW 2016.
Kalb, RE.: Pustular psoriasis: Pathegonesis, clinical manifestations, and diagnosis. UpToDate, Psot TW 2016.
Devins, K; Kalb RE; Helm TN.: Leukemia Cutis. http://emedicine.medscape.com/article/1097702-overview 2015.
Helm, MF; White-Davis, C; Kalb, RE.: Painful Erythema and Edema of the Ears. JAMA Dermatology 151: 785-786, 2015.
Lebwohl, MG; Kavanaugh, A; Armstrong, AW; Van Voorhees, AS; Kalb, RE.: Patient perspectives on psoriasis management: US results of the population-based multinational assessment of psoriasis and psoriatic arthritis survey. Psoriasis Forum 20: 124-132, 2015.
Kalb, RE; Fiorentino, DF; Lebwohl, MG; Toole, J; Poulin, Y; Cohen, AD, et al.: Risk of Serious Infection with Biologic and Systematic Treatment of Psoriasis: Results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). JAMA Dermatology 151: 961-969, 2015.
Gottlieb, AB; Kalb, RE; Langley, RG; Krueger, GG; de Jonh, EM; Guenther, L, et al.: Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systematic and biologic therapies. Journal of Drugs and Dermatology 13: 1441-1448, 2014.
Takeshita, J; Wang, S; Shin, D.B.; Callis Duffin, K; Krueger, G.G.; Kalb, R.E., et al.: Comparative Effectiveness of Less Commonly Used Systematic Monotherapies and Common Combination Therapies for moderate-to-Severe Psoriasis in the Clinical Setting. Journal of the American Academy of Dermatology 71: 1167-75, 2014.
Kalb, RE; Blauvelt, A; Sofen, HL; Chevrier, M; Amato, D; Calabro, S, et al.: Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate to severe psoriasis and inadequate response to etanercept: Results from the PSUNRISE trial. Journal of Drugs and Dermatology 12: 874-880, 2013.